ArticleF&S reports2021
The effect of estrogen therapy on spermatogenesis in transgender women.
Article in F&S reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Congenital aromatase deficiency in an adult male: A case report of clinical course and symptom reversal with estrogen supplementation.Urology case reports · 2026Article
- The Impact of a Formalized Fertility Preservation Program on Access to Care and Sperm Cryopreservation Among Transgender and Nonbinary Patients Assigned Male at Birth.Journal of clinical medicine · 2025Article
- Article
- REPRODUCTIVE HEALTH IN TRANS AND GENDER-DIVERSE PATIENTS: Gonadal tissue cryopreservation in transgender and gender-diverse people.Reproduction (Cambridge, England) · 2024Review
- Clinical management of transgender and non-binary patients in the fertility preservation service: Current evidence.International journal of transgender health · 2024Review
- Exploring Hormone Therapy Effects on Reproduction and Health in Transgender Individuals.Medicina (Kaunas, Lithuania) · 2023Review
- Fertility, Contraception, and Fertility Preservation in Trans Individuals.Deutsches Arzteblatt international · 2023Review
- Fertility counseling guide for transgender and gender diverse people.International journal of transgender health · 2023Article
- Fertility preservation options for transgender and nonbinary individuals.Therapeutic advances in endocrinology and metabolism · 2023Review
- Clinicopathologic features and proposed grossing protocol of orchiectomy specimens performed for gender affirmation surgery.Human pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the histopathologic parameters of orchiectomy specimens obtained after gender-affirming surgery from transgender women who used gender-affirming hormone therapy (GAHT), which included estrogen and spironolactone. Our hypothesis was that an increasing duration of GAHT affects testicular health.
designRetrospective cohort study.
settingTertiary referral center. PATIENTS: All transgender women (individuals assigned male at birth who identified as female) who underwent orchiectomy with or without vaginoplasty between December 2015 and March 2020.
interventionsGAHT (estrogen and spironolactone) in the setting of patients with orchiectomy with or without vaginoplasty.
main outcome measuresDemographic and perioperative data and pathology records were reviewed. The following pathology parameters were recorded: testicular volume, testicular weight, presence of spermatogenesis (active vs. reduced), maturation arrest, testicular atrophy, hyalinization, scarring/fibrosis, and Sertoli cell and Leydig cell phenotypes. The patients were grouped into one of three categories describing the duration of GAHT use: 0-36 months, 37-60 months, and >60 months years. Descriptive statistics were performed and comparisons between outcomes (demographic data and pathology parameters) were made among the GAHT groups.
resultsEighty-five (N = 85) patients underwent orchiectomy during the study period with 85.9% (n = 73) undergoing concurrent vaginoplasty. The mean (SD) age and body mass index of the cohort were 39 ±16 years and 28.4 ± 5.4 kg/m
conclusionsThe duration of GAHT use was not associated with any differences in orchiectomy pathology parameters in patients undergoing gender-affirming surgery, and some patients may still have some spermatogenesis based on the parameters observed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.